Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 7/20 | 0.37 |
| ▸ | HTR2C | P28335 | 7/20 | 0.37 |
| ▸ | HTR2B | P41595 | 6/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046597 | 0.79 | CRBN (0.57) | CRBN | |
| SCHEMBL5863984 | 0.78 | HTR6 (0.42) | ALDH1A1HSD17B10MAPTHTR2AHTR2C | |
| SCHEMBL7236498 | 0.76 | MTR (0.59) | OPRL1HTR2B | |
| SCHEMBL29641124 | 0.74 | CRBN (0.57) | CRBN | |
| SCHEMBL29596179 | 0.74 | CRBN (0.57) | CRBN | |
| SCHEMBL20046182 | 0.74 | CRBN (0.57) | CRBN | |
| SCHEMBL31160690 | 0.74 | CRBN (0.57) | CRBN | |
| SCHEMBL22536049 | 0.74 | CRBN (0.57) | CRBN | |
| SCHEMBL13569676 | 0.74 | PARP1 (0.43) | HTR2AHTR2CHTR2BCRBN | |
| Hydrochloric Acid SCHEMBL22581068 | 0.73 | CRBN (0.56) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6583144-B2 | Piperazine substituted isoquinoline, 1,3-benzoxazine, or 1,3-benzothiazine derivatives; inhibitors against the biosynthesis of triglycerides and secretion of apolipoprotein b and treatment of hyperlipidemia | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| US-20020156276-A1 | Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same | OHKURA NAOTO (JP) | 2002-10-24 | — | — | US | disclosed |
| US-6417362-B1 | PIPERAZINE DERIVATIVES; ARTERIOSCLEROSIS, PANCREATITIS, AND CARDIOVASCULAR DISORDER TREATMENT; SIDE EFFECT REDUCTION | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| EP-0999208-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS AND HYPERLIPEMIA REMEDY CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2000-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156276-A1 | Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same | APOB, PNLIP, NR1H2 | TOP2A 3022/4885ALDH1A1 3399/4885LMNA 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.